Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD
Vicadrostat, with or without background empagliflozin, selectively suppressed aldosterone over cortisol. These findings will be explored in a phase 3 trial program.
Authors
- Sina Pleiner
- KATHERINE R. TUTTLE
- Shimoli Shah (ORCID: https://orcid.org/0000-0003-4927-1517)
- Peter Rossing
- Manuel Monroy Kuhn
- Lisa Cronin
- Denis Delic
- Isabella A Gashaw
Institutions
- University of Copenhagen (DK)
- Boehringer Ingelheim (Germany) (DE)
- Steno Diabetes Centers (DK)
- Providence Regional Medical Center Everett (US)
- University of Washington (US)
- Heidelberg University (DE)
- Kidney Research UK (GB)
- University Hospital Heidelberg (DE)
- Inland Northwest Health Services (US)
- Boehringer Ingelheim (France) (FR)
- University Medical Centre Mannheim (DE)
- Heidelberg University (US)
- Providence Health & Services (US)
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1093/ejendo/lvaf265
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Gilead Sciences
- Novo Nordisk
- Astellas Pharma
- Vifor Pharma
- National Institutes of Health